Omada Health (NASDAQ:OMDA) CEO Sean Duffy Sells 4,063 Shares of Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 4,063 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $14.34, for a total transaction of $58,263.42. Following the transaction, the chief executive officer directly owned 117,598 shares of the company’s stock, valued at approximately $1,686,355.32. This trade represents a 3.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Omada Health Trading Up 0.3%

Shares of OMDA stock traded up $0.04 during trading hours on Thursday, reaching $13.78. The company’s stock had a trading volume of 197,894 shares, compared to its average volume of 1,369,728. The stock has a market capitalization of $811.92 million and a P/E ratio of -81.06. The firm’s fifty day simple moving average is $13.93 and its 200 day simple moving average is $18.52. Omada Health, Inc. has a one year low of $10.28 and a one year high of $28.40.

Omada Health (NASDAQ:OMDA) last announced its quarterly earnings results on Thursday, March 5th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.12. The business had revenue of $75.85 million during the quarter.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on OMDA. Canaccord Genuity Group dropped their price target on Omada Health from $28.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Wells Fargo & Company initiated coverage on Omada Health in a research report on Thursday, January 8th. They issued an “equal weight” rating and a $17.00 target price for the company. BMO Capital Markets lowered their price target on Omada Health from $27.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, March 6th. Barclays cut their price objective on Omada Health from $22.00 to $17.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of Omada Health in a research report on Thursday, January 22nd. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.90.

Institutional Investors Weigh In On Omada Health

A number of hedge funds have recently modified their holdings of OMDA. Geode Capital Management LLC purchased a new stake in shares of Omada Health in the 2nd quarter worth $637,000. Franklin Resources Inc. purchased a new stake in Omada Health in the second quarter worth about $2,695,000. Eisler Capital Management Ltd. purchased a new stake in Omada Health in the second quarter worth about $545,000. XTX Topco Ltd bought a new position in shares of Omada Health in the second quarter worth about $414,000. Finally, Norges Bank purchased a new position in shares of Omada Health during the 2nd quarter valued at about $5,490,000.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.